Insiders Are Loving These 5 Tech and Biotech Stocks
Insiders have lately been showing their love for these three biotech stocks, two tech stocks, and a utility stock with huge share purchases.
Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: TNYA tenayatherapeutics.com
Tenaya Therapeutics is a clinical-stage biotechnology company that discovers and develops potentially curative therapies targeting the underlying genetic and biological drivers of heart disease. Its pipeline has three clinical-stage candidates:
- TN-201, an AAV-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), being studied in the MyPEAK-1 trial.
- TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), being studied in the RIDGE-1 Phase 1b/2 trial. It received FDA RMAT designation in September 2026.
- TN-301, a highly specific small-molecule HDAC6 inhibitor with potential in HFpEF, Duchenne muscular dystrophy and other cardiac, metabolic and muscular conditions. It is being readied for Phase 2 trials expected to begin in the second half of 2027.
The company uses integrated internal capabilities, including modality-agnostic target discovery and validation, to build a portfolio of genetics-based medicines for both rare genetic disorders and more prevalent heart conditions. Tenaya has begun recognizing collaboration revenue and funds operations primarily through equity capital. It reported cash of about $66.8 million as of September 30, 2026, and projects runway into the fourth quarter of 2027. Updated
Insiders have lately been showing their love for these three biotech stocks, two tech stocks, and a utility stock with huge share purchases.
Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the past week.
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Tenaya Therapeutics is a clinical-stage biotechnology company that discovers and develops potentially curative therapies targeting the underlying genetic and biological drivers of heart disease.
The Wall Street consensus 12-month price target for TNYA is $3.67.